Alexander Zehnder, CureVac CEO (via website)

Cure­Vac claims de­lay in Ger­man court over al­leged in­fringe­ment of its Covid-19 vac­cine by BioN­Tech a sign in its fa­vor

Cure­Vac is ex­pect­ing good news in its patent in­fringe­ment cas­es for com­po­nents of its Covid-19 vac­cine against Pfiz­er part­ner BioN­Tech in Ger­many af­ter a court …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.